AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 81.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 80,870 shares of the biotechnology company's stock after buying an additional 36,365 shares during the period. Squarepoint Ops LLC owned approximately 0.27% of AnaptysBio worth $1,071,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after acquiring an additional 143,584 shares in the last quarter. Fairmount Funds Management LLC acquired a new stake in AnaptysBio in the 4th quarter valued at $24,050,000. Boxer Capital Management LLC purchased a new position in AnaptysBio in the fourth quarter valued at about $17,212,000. Sanofi acquired a new position in shares of AnaptysBio during the fourth quarter worth about $10,882,000. Finally, Geode Capital Management LLC boosted its position in shares of AnaptysBio by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock worth $6,444,000 after buying an additional 21,196 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently commented on ANAB. Wedbush reissued an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 29th. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $22.00 to $38.00 in a research report on Wednesday. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Johnson Rice reaffirmed a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Finally, Wells Fargo & Company boosted their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $42.38.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB traded down $2.25 during midday trading on Wednesday, reaching $21.27. The company had a trading volume of 1,967,023 shares, compared to its average volume of 623,382. The stock has a market capitalization of $624.91 million, a P/E ratio of -3.50 and a beta of -0.20. The stock's fifty day moving average price is $19.95 and its 200-day moving average price is $18.31. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. As a group, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has initiated a stock buyback plan on Monday, March 24th that permits the company to buyback $75.00 million in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.